FDA de­ter­mines GLP-1s not linked to sui­ci­dal thoughts or ac­tions in pre­lim­i­nary re­view

The FDA found that the use of GLP-1s to treat di­a­betes and obe­si­ty do not cause sui­ci­dal thoughts or ac­tions in a pre­lim­i­nary re­view of clin­i­cal tri­als and safe­ty da­ta re­port­ed to the agency.

The FDA has spent the past sev­er­al months eval­u­at­ing re­ports of sui­ci­dal thoughts and ac­tions re­port­ed via the agency’s ad­verse event re­port­ing sys­tem and de­ter­mined that the re­ports did not in­di­cate a clear con­nec­tion to the drugs, un­der­scor­ing that the da­ta pro­vid­ed are lim­it­ed and can be in­flu­enced by oth­er fac­tors. Sim­i­lar­ly, the agency’s re­view of clin­i­cal tri­als of GLP-1s did not find a link be­tween the drugs and sui­ci­dal thoughts and ac­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER